Iteos Therapeutics, Inc. ( (ITOS) ) has released its Q2 earnings. Here is a breakdown of the information Iteos Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
iTeos Therapeutics, Inc. is a biotechnology company specializing in the development of immuno-oncology therapeutics aimed at treating cancer, with a focus on monoclonal antibodies and small molecules targeting key cancer resistance mechanisms. The company recently announced its intention to wind down clinical and operational activities following the termination of its collaboration with GlaxoSmithKline (GSK) and the belrestotug development program. In its latest earnings report, iTeos Therapeutics reported a significant net loss of $113.3 million for the first half of 2025, compared to a $45.3 million loss in the same period of 2024, primarily due to increased research and development expenses and restructuring costs. The company also highlighted a substantial decrease in cash and cash equivalents from $686.9 million at the end of 2024 to $623.1 million by mid-2025. Despite the financial challenges, iTeos continues to explore strategic alternatives to maximize shareholder value, although there is substantial doubt about its ability to continue as a going concern. Looking forward, the company’s management is focused on completing the wind-down process and evaluating potential strategic alternatives, including a possible merger or dissolution, to address its financial and operational challenges.